Physician profile
Dawn E Best
NPI 1619146768
$1,379.35
in general payments reported to CMS, 2019-2025
19 companies · $747 in 2025
The $747 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $48.15 · 2023: $31.14 · 2024: $127 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580 · Travel and Lodging: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.66 |
| Travel and Lodging | $325.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $772.61 | 2024-2025 | Impella |
| Abbott Laboratories | $92.48 | 2021-2025 | Pressurewire |
| Edwards Lifesciences Corporation | $56.05 | 2024-2025 | Sapien 3 Ultra Resilia |
| Amgen INC. | $50.31 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $46.63 | 2021 | |
| Artivion, INC. | $41.49 | 2021 | |
| Boston Scientific Corporation | $40.36 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $36.32 | 2021 | |
| Pfizer INC. | $26.69 | 2021 | |
| Merck Sharp & Dohme LLC | $26.55 | 2021 | |
| Getinge USA Sales, LLC | $26.00 | 2021 | |
| Novo Nordisk INC | $24.63 | 2021 | |
| Kerecis Limited | $22.41 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Esperion Therapeutics, INC. | $19.12 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.35 | 2021 | |
| Lsi Solutions INC | $15.79 | 2023 | Cor Knot |
| Atricure, INC. | $15.35 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Best listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.